Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Autolus TherapeuticsFRA:6A3A +3.17%70 Days Payable is 9.13 as of Mar. 2026, which is 57% below its 10-year median of 21.39. GuruFocus rates FRA:6A3A with a GF Score™ of 70/100 and a GF Value™ of €17.65 (Possible Value Trap). The stock has 7 warning signs investors should review. Among 701 Biotechnology companies, Autolus Therapeutics ranks worse than 90.3% on this metric.
The historical rank and industry rank for Autolus Therapeutics's Days Payable or its related term are showing as below:
FRA:6A3A'
s Days Payable Range Over the Past 10 Years
Min: 9.57 Med: 21.39 Max: 33.21
Current: 18.28
During the past 10 years, Autolus Therapeutics's highest Days Payable was 33.21. The lowest was 9.57. And the median was 21.39.
FRA:6A3A's Days Payable is ranked worse than 90.3% of 701
companies
in the Biotechnology industry
Industry Median: 112.84
vs FRA:6A3A: 18.28
Autolus Therapeutics's Days Payable
declined
from Mar. 2025 (16.50) to Mar. 2026 (9.13).
It may suggest that Autolus Therapeuticsaccelerated paying its suppliers.
Autolus Therapeutics Days Payable Related Terms
Autolus Therapeutics Days Payable Historical Data
* Premium members only.
The historical data trend for Autolus Therapeutics's Days Payable can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:6A3A vs FBRX, SGMT, EDIT: Days Payable Comparison
For the Biotechnology subindustry, Autolus Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Autolus Therapeutics Days Payable vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Autolus Therapeutics's Days Payable distribution charts can be found below:
* The bar in red indicates where Autolus Therapeutics's Days Payable falls into.
Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.
Autolus Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Autolus Therapeutics (FRA:6A3A) has a Days Payable of 9.13 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Autolus Therapeutics and its competitors. This is 57% below median its historical median of 21.39. Over the past decade, Autolus Therapeutics' Days Payable has ranged from 9.57 to 33.21. According to the industry distribution chart, Autolus Therapeutics ranks #633 out of 701 companies in the Biotechnology industry, placing it in the top 90.3%.
Is Autolus Therapeutics' Days Payable too high?
Autolus Therapeutics' current Days Payable of 9.13 is 57% below median its 10-year median of 21.39. Over the past 10 years, this metric has ranged from a low of 9.57 to a high of 33.21. The Biotechnology industry median Days Payable is 112.84. Autolus Therapeutics' value of 9.13 is 91.9% below this industry median. Based on the distribution chart, Autolus Therapeutics ranks #633 out of 701 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Autolus Therapeutics has a GF Score™ of 70/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Autolus Therapeutics' Days Payable compare to FBRX and SGMT?
According to the Biotechnology industry distribution chart, Autolus Therapeutics ranks #633 out of 701 companies for Days Payable. This places Autolus Therapeutics in the lower half of its industry. The industry median Days Payable is 112.84. Autolus Therapeutics' value of 9.13 is 91.9% below this benchmark. Historically, Autolus Therapeutics' own Days Payable has ranged from 9.57 to 33.21 over the past decade. While the company's 10-year median is 21.39 vs. the industry median of 112.84, Autolus Therapeutics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Payable for a Biotechnology company?
The median Days Payable among Biotechnology companies is 112.84, based on 701 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Autolus Therapeutics's current Days Payable of 9.13 is 91.9% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Payable mean?
A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Autolus Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 112.84 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Autolus Therapeutics's current Days Payable is 9.13, which is 57% below median its own 10-year median of 21.39. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Autolus Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Autolus Therapeutics (FRA:6A3A) is currently considered Possible Value Trap. The stock's GF Value™ is €17.65, compared to a current price of €1.30 — trading 92.6% below its estimated fair value. The current Days Payable is 9.13, which is 57% below median its 10-year median of 21.39 and 91.9% below the Biotechnology industry median of 112.84. Autolus Therapeutics' overall GF Score™ is 70/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Payable calculated?
Days Payable is calculated from a company's financial statements. For Autolus Therapeutics (FRA:6A3A), the current Days Payable is 9.13 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Autolus Therapeutics (FRA:6A3A) Overvalued in 2026?
Based on GuruFocus' analysis, Autolus Therapeutics stock appears to be undervalued.
The current stock price of €1.30 is trading 92.6% below its estimated GF Value™ of €17.65.
GuruFocus considers Autolus Therapeutics to be Possible Value Trap.
Key valuation signals for FRA:6A3A:
Days Payable: 9.13 (57% below median its 10-year median of 21.39)
GF Value™: €17.65 vs. price of €1.30 (92.6% below fair value)
Industry Position: 91.9% below the Biotechnology median (#633 of 701)
No single metric tells the full story. See the FRA:6A3A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Autolus Therapeutics PLC is a biopharmaceutical company developing next-generation programmed T-cell therapies for the treatment of cancer. The company's clinical-stage pipeline comprises Obe-cel (obecabtagene autoleucel), AUTO1/22, AUTO3, AUTO5, AUTO6, AUTO7 & AUTO8. Company's T cell programming technologies tailors therapies to address the specific disease targeting and introduce new programming modules into a patient's T cells to give those T cells improved properties to recognize target cells and overcome fundamental disease defense mechanisms.
70GF Score
Get the complete analysis for FRA:6A3A
Days Payable is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:6A3A has been successfully added to your 
